Os Therapies Inc (OSTX) — 10-Q Filings

10-Q Filings (5)

• OSTX Net Loss Soars 159% Amid R&D Surge, Cash Dwindles — Nov 14, 2025 Risk: high
  OS Therapies Inc. (OSTX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $15,293,011, compared to $5,891,704
• OS Therapies Inc. Files Q2 2025 10-Q Report — Aug 18, 2025 Risk: low
  OS Therapies Inc. filed its 10-Q for the quarterly period ended June 30, 2025. The company, incorporated in Delaware, operates in the Pharmaceutical Preparation
• OS Therapies Inc. Files Q1 2025 10-Q Report — May 15, 2025 Risk: low
  OS Therapies Inc. filed its 10-Q for the quarterly period ended March 31, 2025. The company, incorporated in Delaware with its principal executive offices in Gr
• OS Therapies Inc. Files Q2 2024 10-Q Report — Aug 14, 2024 Risk: low
  OS Therapies Inc. filed its quarterly report on June 30, 2024, detailing its financial performance. The company, incorporated in Delaware, operates in the Pharm
• OS Therapies Files Q1 2024 10-Q Report — May 20, 2024 Risk: medium
  OS Therapies Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2024. The company, incorporated in Delaware with its principal executi

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX